Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Patent Office (EPO) has issued EPO patent grant no 1565494 to Genesis Biopharma providing coverage on Genesis anti-CD55 antibodies for use as a therapeutic treatment in multiple cancers.
Subscribe to our email newsletter
Genesis Biopharma is developing its anti-CD55 antibody therapy to neutralize a key cancer defense mechanism that has been found to be over-expressed in more than 80% of solid tumors.
The patent ‘CD55-Interaction Partners and the Uses Thereof’ covers use of the Genesis anti-CD55 antibodies both as a monotherapy and as a combination therapy, including their use in combination with marketed antibody therapies and expire in 2023.
Patent coverage includes France, Germany, UK, Spain, Italy and Switzerland.
Genesis Biopharma is pursuing related patent applications for its anti-CD55 program in the US, Japan, Hong Kong, Australia and Canada.
Genesis Biopharma president and CEO Robert Brooke said that this patent supports our intellectual property strategy for our anti-CD55 program and provides technology coverage in the major European healthcare market, and also bodes well for the pending patent applications in other nations.
Further, Genesis Biopharma plans to seek partnerships with pharmaceutical and biotechnology companies to support its anti-CD55 clinical development programs at the earliest appropriate time.